Sylvan, a Beijing, China-based manufacturer of fungal biotechnology solutions, received an investment from Novo Holdings.
The amount of the deal was not disclosed. KKR will remain the company’s majority shareholder.
The new capital will support Sylvan’s expansion by enabling increased production capacity, upgraded R&D infrastructure, and penetration into high-growth markets, particularly in Asia. Sylvan will also benefit from Novo Holdings’ extensive network and sector expertise to further strengthen its position in the global mushroom spawn market and develop new high-impact bio-products, such as fungi-based materials, biopesticides, and nutritional supplements.
Founded in 1932 and led by Jackie Qi, CEO, Sylvan is a large mushroom spawn and fungal biotechnology company that creates sustainable solutions to address global challenges in food, health, agriculture, and materials. Today, the company operates multiple production facilities around the world and serves customers across 65 countries.
FinSMEs
03/04/2025